BioPharmSignal logoBioPharmSignal

Biotech News

Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting

Nektar Therapeutics (NKTR)Nektar Therapeutics2026-06-25 13:46 ESTClinical readout

Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both moderate and severe atopic dermatitis patients Rezpegaldesleukin proof-of-concept data in alopecia areata patients presented as a late-breaking research oral presentation SAN FRANCISCO,

Open original release

Related news

NKTRNektar Therapeutics2026-06-25 13:46 EST

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York

NKTRNektar Therapeutics2026-06-25 13:46 EST

Nektar Therapeutics Reports First Quarter 2026 Financial Results

NKTRNektar Therapeutics2026-06-25 13:46 EST

Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

NKTRNektar Therapeutics2026-06-25 13:46 EST

Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting

NKTRNektar Therapeutics2026-06-25 13:46 EST

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NKTRNektar Therapeutics2026-06-25 13:46 EST

Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets

NKTRNektar Therapeutics2026-06-25 13:46 EST

Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

NKTRNektar Therapeutics2026-06-25 13:46 EST

Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering

NKTRNektar Therapeutics2026-06-25 13:46 EST

Nektar Therapeutics Announces Proposed Public Offering

NKTRNektar Therapeutics2026-06-25 13:46 EST

52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin

View all latest news

Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

NKTRNektar Therapeutics2026-06-26 06:08 EST

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York

NKTRNektar Therapeutics2026-06-26 06:08 EST

Nektar Therapeutics Reports First Quarter 2026 Financial Results

NKTRNektar Therapeutics2026-06-26 06:08 EST

Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

NKTRNektar Therapeutics2026-06-26 06:08 EST

Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting

NKTRNektar Therapeutics2026-06-26 06:08 EST

Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States